. 2022 Jan 23;94(5):2102–2107. doi: 10.1002/jmv.27595

Table 1.

Characteristics of included studies

Author, year	Study design	Study period	Study sites	Study population	Regimen of melatonin	No of patients
Author, year	Study design	Study period	Study sites	Study population	Regimen of melatonin	Study group	Control group
Alizade et al. (2021) ¹²	Randomized, single‐blinded trial	Between June 30, 2020 and August 5, 2020	Tehran University of Medical Sciences in Iran	Mild to moderate COVID‐19 patients	Melatonin at 6 mg before bedtime for 14 days	14	17
Farnoosh et al. (2021) ¹³	Randomized, double‐blind clinical trial	From April 25, 2020 to June 5, 2020	Baqiyatallah University of Medical Sciences in Iran	Mild to moderate COVID‐19	Melatonin at 3 mg three times daily for 14 days	24	20
Mousavi et al. (2021) ¹⁴	Randomized open‐label, active‐controlled clinical trial	From April 14, 2020 to June 15, 2020	Mazandaran University of Medical Sciences in Iran	Hospitalized patients with COVID‐19	Melatonin at 3 mg before bedtime for 7 days	48	48